Eptifibatide

Eptifibatide

SCHEMBL18504808

NC(=O)C1CSSCCC(=O)N[C@@H](CCCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N2CCC[C@H]2C(=O)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ITGA2BITGB3

The experimentally established mechanism targets of Eptifibatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ITGB3 known ✓ P05106 5/20 1.00
ITGA2B known ✓ P08514 3/20 1.00
ITGAV P06756 5/20 1.00
MC3R P41968 5/20 0.59
MC5R P33032 4/20 0.59
MC4R P32245 3/20 0.59
ITGA5 P08648 4/20 0.57
ITGB1 P05556 2/20 0.57
ITGB5 P18084 2/20 0.57
LDLR P01130 9/20 0.57
PCSK9 Q8NBP7 9/20 0.57
KLK5 Q9Y337 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eptifibatide SCHEMBL43237 1.00 ITGB3 (1.00) ITGB3ITGAVITGA2BMC3RMC5R
Eptifibatide SCHEMBL22193879 1.00 ITGB3 (1.00) ITGB3ITGAVITGA2BMC3RMC5R
Eptifibatide SCHEMBL29353236 1.00 ITGB3 (1.00) ITGB3ITGAVITGA2BMC3RMC5R
Eptifibatide SCHEMBL16883987 1.00 ITGB3 (1.00) ITGB3ITGAVITGA2BMC3RMC5R
Eptifibatide SCHEMBL1649793 1.00 ITGB3 (1.00) ITGB3ITGAVITGA2BMC3RMC5R
Eptifibatide SCHEMBL16884017 1.00 ITGB3 (1.00) ITGB3ITGAVITGA2BMC3RMC5R
SCHEMBL29356871 0.98 ITGB3 (0.97) ITGB3ITGAVITGA2BMC3RMC5R
SCHEMBL16883997 0.93 ITGB3 (0.87) ITGB3ITGAVITGA2BLDLRPCSK9
SCHEMBL24433345 0.93 ITGB3 (0.86) ITGB3ITGAVITGA2BMC3RMC5R
SCHEMBL16883930 0.91 ITGB3 (0.84) ITGB3ITGAVITGA2BMC3RMC5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044236-A1 Integrin Antagonists THE GENERAL HOSPITAL CORPORATION 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044236-A1 Integrin Antagonists ITGA5, ITGB5, ITGB3 ITGB3 3/4885ITGA2B 7/4885ITGAV 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.